Characteristics | All (n = 370, %) | LYL1 amplification (n = 22, %) | LYL1 non-amplification (n = 348, %) | P |
---|---|---|---|---|
Age, years | < 0.001 | |||
Mean ± SD | 63.1 ± 11.0 | 72.7 ± 8.0 | 62.5 ± 10.9 | |
Menopausea | 0.393 | |||
Yes | 313 (84.6) | 0 (0) | 27 (7.8) | |
No | 27 (7.3) | 21 (95.5) | 292 (83.9) | |
Unknown | 30 (8.1) | 1 (4.5) | 29 (8.3) | |
Diabetes | 0.774 | |||
Yes | 83 (22.4) | 5 (22.7) | 78 (22.4) | |
No | 221 (59.7) | 11 (50.0) | 210 (60.3) | |
Unknown | 66 (17.8) | 6 (27.3) | 60 (17.2) | |
Hypertension | 0.420 | |||
Yes | 195 (52.7) | 11 (50.0) | 184 (52.9) | |
No | 135 (36.5) | 5 (22.7) | 130 (37.4) | |
Unknown | 40 (10.8) | 6 (27.3) | 34 (9.8) | |
Histologic type | < 0.001 | |||
Endometrioid | 304 (82.2) | 6 (27.3) | 298 (85.6) | |
Serous | 52 (14.1) | 13 (59.1) | 39 (11.2) | |
Mixed | 14 (3.8) | 3 (13.6) | 11 (3.2) | |
Grade | < 0.001 | |||
1 | 88 (23.8) | 0 (0) | 88 (25.3) | |
2 | 106 (28.6) | 1 (4.5) | 105 (30.2) | |
3 | 176 (47.6) | 21 (95.5) | 155 (44.5) | |
FIGO stage | 0.003 | |||
I | 254 (68.6) | 9 (40.9) | 245 (70.4) | |
II | 24 (6.5) | 2 (9.1) | 22 (6.3) | |
III | 72 (19.5) | 9 (40.9) | 63 (18.1) | |
IV | 17 (4.6) | 2 (9.1) | 15 (4.3) | |
Unknown | 3 (0.8) | 0 (0) | 3 (0.9) | |
TCGA type | ||||
POLE ultra-mutated | 17 (4.6) | 0 (0) | 17 (4.9) | 0.612 |
MSI hyper-mutated | 65 (17.6) | 0 (0) | 65 (18.7) | 0.019 |
Low copy number | 90 (24.3) | 0 (0) | 90 (25.9) | 0.006 |
High copy-number | 58 (15.7) | 16 (72.7) | 42 (12.1) | < 0.001 |
Indeterminate | 140 (37.8) | 6 (27.3) | 134 (38.5) | 0.292 |
MSI status | < 0.001 | |||
Stable | 223 (60.2) | 22 (100.0) | 201 (57.8) | |
Low | 19 (5.1) | 0 (0) | 19 (5.5) | |
High | 125 (33.7) | 0 (0) | 125 (35.9) | |
Indeterminate | 3 (0.8) | 0 (0) | 3 (0.9) | |
Adjuvant treatment | ||||
Chemotherapy only | 110 (29.7) | 11 (50.0) | 99 (28.4) | 0.032 |
Radiation only | 55 (14.9) | 2 (9.1) | 53 (15.2) | 0.756 |
Chemotherapy + Radiation | 23 (6.2) | 1 (4.5) | 22 (6.3) | 1.000 |
Hormone therapy | 17 (4.6) | 0 (0) | 17 (4.9) | 0.612 |